Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab, Binimetinib and Talazoparib in RAS-mutant Solid Tumors
NCT03637491Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of avelumab, binimetinib, talazoparib in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), solid tumor, sponsored by Pfizer. Started Aug 2018; status: terminated.
02
Drugs
avelumabbinimetinibtalazoparib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT03637491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637491.